PhaseRx, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PZRXQ research report →
Companywww.phaserx.com
PhaseRx, Inc. , a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell.
- CEO
- Robert W. Overell
- IPO
- 2016
- Employees
- 10
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $1.17K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.24
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 101.72%
- ROIC
- -122.20%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-20,137,000 · -172.97%
- EPS
- $-2.68 · -185.11%
- Op Income
- $-18,330,000
- FCF YoY
- -63.80%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.55
- Avg Volume
- 299.492
Get TickerSpark's AI analysis on PZRXQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PZRXQ Coverage
We haven't published any research on PZRXQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PZRXQ Report →